Regional ASCO 2022 Data Releases from the BioHealth Capital Region and Greater Philadelphia
NOTE: This list will be continually updated. To submit your release, please email Sarah Ellinwood ([email protected])
BioHealth Capital Region (Maryland, Virginia, and DC)
- I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
- Delfi Diagnostics to Present at 2022 ASCO Annual Meeting on Multiple Applications for its Next-Generation Liquid Biopsy Platform
- Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development
- CEL-SCI Announces Publication of ASCO 2022 Abstracts
- CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
- Arcellx To Present New Clinical Data From Its CART-DdBCMA Phase 1 Trial In Patients With Relapsed Or Refractory Multiple Myeloma In An Oral Abstract Session At The 2022 American Society Of Clinical Oncology (ASCO) Annual Meeting
- The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3%
- Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors who Progressed on Immunotherapies
- NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors
Cellicon Valley (Greater Philadelphia)
- Carisma Therapeutics to Present Latest Data from Phase 1 Clinical Trial of Engineered Macrophage Therapy at 2022 ASCO Annual Meeting
- INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022
- Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
- Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
- Clinical Responses Reported across Patient Subgroups with Adaptimmune’s Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas – BLA Submission On-Track
- PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022
- Jubilant Therapeutics Inc. Reports Development of Orally Available and Brain Penetrant Small Molecule Inhibitors of PD-L1 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study
- Linnaeus Therapeutics Announces Presentation of Positive Clinical Data of LNS8801 at 2022 ASCO Annual Meeting
- About the Author
- Latest Posts
BioBuzz is a community led, experience focused, biotech and life sciences media and events company. BioBuzz highlights regional breaking news, industry professionals, jobs, events, and resources for business and career growth. Their weekly newsletter is subscribed to by thousands in the BioHealth Capital Region and Greater Philadelphia as the go-to for industry updates.
